BBB. Nebiyou Bekele

B. Nebiyou Bekele

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


B. Nebiyou Bekele has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Bayesian Model to Assess a Binary Measurement System When No Gold Standard System Is Available

    by Daniel P. Beavers, James D. Stamey, B. Nebiyou Bekele

    A repeated binary testing framework is implemented when quality inspections fallibly classify units as either conforming or not conforming to quality standards. We develop a Bayesian approach to the statistical analysis of repeated binary testing data. Our approach allows an investigator to characterize and incorporate prior information on the unknown conforming rate and misclassification parameters. Our model assumes beta density priors and we develop a Markov chain Monte Carlo approach for representing posterior densities. In addition, we propose methods for the determination of necessary sample sizes based on average posterior variance criteria and average credible interval length criteria.


  • Risk‐Group‐Specific Dose Finding Based on an Average Toxicity Score

    by B. Nebiyou Bekele, Yisheng Li, Yuan Ji

    Summary We propose a Bayesian dose-finding design that accounts for two important factors, the severity of toxicity and heterogeneity in patients' susceptibility to toxicity. We consider toxicity outcomes with various levels of severity and define appropriate scores for these severity levels. We then use a multinomial-likelihood function and a Dirichlet prior to model the probabilities of these toxicity scores at each dose, and characterize the overall toxicity using an average toxicity score (ATS) parameter. To address the issue of heterogeneity in patients' susceptibility to toxicity, we categorize patients into different risk groups based on their susceptibility. A Bayesian isotonic transformation is applied to induce an order-restricted posterior inference on the ATS. We demonstrate the performance of the proposed dose-finding design using simulations based on a clinical trial in multiple myeloma.


  • Assessing Toxicities in a Clinical Trial: Bayesian Inference for Ordinal Data Nested within Categories

    by L.G. Leon‐Novelo, X. Zhou, B. Nebiyou Bekele, P. Müller

    SummaryThis article addresses modeling and inference for ordinal outcomes nested within categorical responses. We propose a mixture of normal distributions for latent variables associated with the ordinal data. This mixture model allows us to fix without loss of generality the cutpoint parameters that link the latent variable with the observed ordinal outcome. Moreover, the mixture model is shown to be more flexible in estimating cell probabilities when compared to the traditional Bayesian ordinal probit regression model with random cutpoint parameters. We extend our model to take into account possible dependence among the outcomes in different categories. We apply the model to a randomized phase III study to compare treatments on the basis of toxicities recorded by type of toxicity and grade within type. The data include the different (categorical) toxicity types exhibited in each patient. Each type of toxicity has an (ordinal) grade associated to it. The dependence among the different types of toxicity exhibited by the same patient is modeled by introducing patient‐specific random effects.


  • Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity Outcomes

    by Yuan Ji, B. Nebiyou Bekele

    Summary We present an outcome‐adaptive randomization (AR) scheme for comparative clinical trials in which the primary endpoint is a joint efficacy/toxicity outcome. Under the proposed scheme, the randomization probabilities are unbalanced adaptively in favor of treatments with superior joint outcomes characterized by higher efficacy and lower toxicity. This type of scheme is advantageous from the patients' perspective because on average, more patients are randomized to superior treatments. We extend the approximate Bayesian time‐to‐event model in Cheung and Thall (2002, Biometrics 58, 89–97) to model the joint efficacy/toxicity outcomes and perform posterior computation based on a latent variable approach. Consequently, this allows us to incorporate essential information about patients with incomplete follow‐up. Based on the computed posterior probabilities, we propose an AR scheme that favors the treatments with larger joint probabilities of efficacy and no toxicity. We illustrate our methodology with a leukemia trial that compares three treatments in terms of their 52‐week molecular remission rates and 52‐week toxicity rates.


  • Open Access

    Monitoring late-onset toxicities in phase I trials using predicted risks

    by B. Nebiyou Bekele, Yuan Ji, Yu Shen, Peter F. Thall

    Late-onset (LO) toxicities are a serious concern in many phase I trials. Since most dose-limiting toxicities occur soon after therapy begins, most dose-finding methods use a binary indicator of toxicity occurring within a short initial time period. If an agent causes LO toxicities, however, an undesirably large number of patients may be treated at toxic doses before any toxicities are observed. A method addressing this problem is the time-to-event continual reassessment method (TITE-CRM, Cheung and Chappell, 2000). We propose a Bayesian dose-finding method similar to the TITE-CRM in which doses are chosen using time-to-toxicity data. The new aspect of our method is a set of rules, based on predictive probabilities, that temporarily suspend accrual if the risk of toxicity at prospective doses for future patients is unacceptably high. If additional follow-up data reduce the predicted risk of toxicity to an acceptable level, then accrual is restarted, and this process may be repeated several times during the trial. A simulation study shows that the proposed method provides a greater degree of safety than the TITE-CRM, while still reliably choosing the preferred dose. This advantage increases with accrual rate, but the price of this additional safety is that the trial takes longer to complete on average.


  • A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose‐Finding Trial

    by B. Nebiyou Bekele, Yu Shen

    In this article, we propose a Bayesian approach to phase I/II dose-finding oncology trials by jointly modeling a binary toxicity outcome and a continuous biomarker expression outcome. We apply our method to a clinical trial of a new gene therapy for bladder cancer patients. In this trial, the biomarker expression indicates biological activity of the new therapy. For ethical reasons, the trial is conducted sequentially, with the dose for each successive patient chosen using both toxicity and activity data from patients previously treated in the trial. The modeling framework that we use naturally incorporates correlation between the binary toxicity and continuous activity outcome via a latent Gaussian variable. The dose-escalation/de-escalation decision rules are based on the posterior distributions of both toxicity and activity. A flexible state-space model is used to relate the activity outcome and dose. Extensive simulation studies show that the design reliably chooses the preferred dose using both toxicity and expression outcomes under various clinical scenarios.